Incyte Corporation

Incyte Corporationverified

INCY

Price:

$52.35

Market Cap:

$11.75B

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase II/III clinical tr...[Read more]

Industry

Biotechnology

IPO Date

1993-11-04

Stock Exchange

NASDAQ

Ticker

INCY

The PE Ratio as of April 2024 (TTM) for Incyte Corporation (INCY) is 19.75

According to Incyte Corporation’s latest financial reports and current stock price. The company's current PE Ratio is 19.75. This represents a change of -66.96% compared to the average of 59.77 of the last 4 quarters.

Incyte Corporation (INCY) Historical PE Ratio (quarterly & annually)

How has INCY PE Ratio performed in the past?

The mean historical PE Ratio of Incyte Corporation over the last ten years is 304.32. The current 19.75 PE Ratio has changed 548.99% with respect to the historical average. Over the past ten years (40 quarters), INCY's PE Ratio was at its highest in in the December 2016 quarter at 532.82. The PE Ratio was at its lowest in in the June 2017 quarter at -517.25.

Quarterly (TTM)
Annual

Average

304.32

Median

32.74

Minimum

-252.10

Maximum

2.98K

Incyte Corporation (INCY) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Incyte Corporation PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 206.88%

Maximum Annual PE Ratio = 2.98K

Minimum Annual Increase = -1282.99%

Minimum Annual PE Ratio = -252.10

Quarterly (TTM)
Annual
YearPE RatioChange
202323.50-55.11%
202252.34206.88%
202117.06-126.59%
2020-64.15-252.76%
201941.99-65.96%
2018123.35-299.34%
2017-61.88-134.23%
2016180.75-93.94%
20152.98K-1282.99%
2014-252.10178.98%

Incyte Corporation (INCY) Average PE Ratio

How has INCY PE Ratio performed in the past?

The current PE Ratio of Incyte Corporation (INCY) is less than than its 3-year, greater than its 5-year, and less than than its 10-year historical averages

3-year avg

30.97

5-year avg

14.15

10-year avg

304.32

Incyte Corporation (INCY) PE Ratio vs. Peers

How is INCY’s PE Ratio compared to its peers?

Incyte Corporation’s PE Ratio is greater than Alnylam Pharmaceuticals, Inc. (-41.20), greater than United Therapeutics Corporation (11.36), greater than Ultragenyx Pharmaceutical Inc. (-5.67), greater than Apellis Pharmaceuticals, Inc. (-10.90), greater than BeiGene, Ltd. (-15.29), less than BioMarin Pharmaceutical Inc. (99.64), greater than ImmunoGen, Inc. (-122.93), greater than Prometheus Biosciences, Inc. (-81.93), greater than Arrowhead Pharmaceuticals, Inc. (-8.08), greater than Ionis Pharmaceuticals, Inc. (-16.04), greater than Axsome Therapeutics, Inc. (-13.43), greater than Sarepta Therapeutics, Inc. (-20.19), greater than ACADIA Pharmaceuticals Inc. (-45.23), greater than Amicus Therapeutics, Inc. (-20.55), greater than Denali Therapeutics Inc. (-15.23), greater than argenx SE (-71.12), greater than Harmony Biosciences Holdings, Inc. (13.31),

Build a custom stock screener for Incyte Corporation (INCY) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Incyte Corporation using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Incyte Corporation (INCY) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Incyte Corporation or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the PE Ratio?

How can you use the PE Ratio?

What is Incyte Corporation's PE Ratio?

How is the PE Ratio calculated for Incyte Corporation (INCY)?

What is the highest PE Ratio for Incyte Corporation (INCY)?

What is the 3-year average PE Ratio for Incyte Corporation (INCY)?

What is the 5-year average PE Ratio for Incyte Corporation (INCY)?

How does the current PE Ratio for Incyte Corporation (INCY) compare to its historical average?